Australia markets closed

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
33.56-0.35 (-1.03%)
As of 02:24PM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 6.48B
Enterprise value 5.75B
Trailing P/E 28.29
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)8.12
Price/book (mrq)3.93
Enterprise value/revenue 7.20
Enterprise value/EBITDA 19.47

Trading information

Stock price history

Beta (5Y monthly) 0.44
52-week change 311.60%
S&P500 52-week change 3-16.16%
52-week high 348.72
52-week low 329.62
50-day moving average 335.84
200-day moving average 339.18

Share statistics

Avg vol (3-month) 32M
Avg vol (10-day) 31.38M
Shares outstanding 5197.2M
Implied shares outstanding 6N/A
Float 893.27M
% held by insiders 148.31%
% held by institutions 19.29%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.41
Forward annual dividend yield 41.23%
Trailing annual dividend rate 30.31
Trailing annual dividend yield 30.92%
5-year average dividend yield 4N/A
Payout ratio 434.89%
Dividend date 3N/A
Ex-dividend date 426 May 2022
Last split factor 21:1
Last split date 326 May 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 June 2022

Profitability

Profit margin 28.51%
Operating margin (ttm)24.34%

Management effectiveness

Return on assets (ttm)6.31%
Return on equity (ttm)14.78%

Income statement

Revenue (ttm)799.17M
Revenue per share (ttm)4.04
Quarterly revenue growth (yoy)1.70%
Gross profit (ttm)640.76M
EBITDA 242.31M
Net income avi to common (ttm)227.85M
Diluted EPS (ttm)1.16
Quarterly earnings growth (yoy)67.30%

Balance sheet

Total cash (mrq)830.04M
Total cash per share (mrq)4.21
Total debt (mrq)105.99M
Total debt/equity (mrq)6.43
Current ratio (mrq)4.28
Book value per share (mrq)8.35

Cash flow statement

Operating cash flow (ttm)339.44M
Levered free cash flow (ttm)-35.38M